You can buy or sell Galapagos and other stocks, options, ETFs, and crypto commission-free!
Galapagos NV American Depositary Shares, also called Galapagos, is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. Read More The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Mechelen, Brussels Region
52 Week High
52 Week Low
Research And Development
Simply Wall St12h
The Galapagos (AMS:GLPG) Share Price Is Up 136% And Shareholders Are Boasting About It
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick a company that is really flourishing, you can make more than 100%. For instance the Galapagos NV (AMS:GLPG) share price is 136% higher than it was three years ago. How nice for those who held the stock! We note the stock price is up 3.7% in the last seven days. Check out our latest analysis for Galapagos Galapagos isn’t a profitable company, so it is unlikely we’...
Associated PressMar 20
Galapagos increases share capital through warrant exercises
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. Mechelen, Belgium; 20 March 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 149,370 new ordinary shares on 20...
The Motley FoolMar 9
3 Top Biotech Stocks to Buy in March
Biotech investors are having a great start to 2019. Shares of the SPDR S&P Biotech ETF are up 19% since Jan. 1, which is a heck of a run in such a short time. But which biotech stocks are worth a closer look during this recent rally? We asked three Motley Fool contributors to weigh in, and they picked Galapagos (NASDAQ:GLPG), Celgene (NASDAQ:CELG), and Zealand Pharma (NASDAQ:ZEAL). Big news is on deck for this clinical-stage biotech Todd Campbell: (Galapagos): This foreign-based biotech might not be on y...
Available Apr 25, After Hours